Neuland Laboratories Limited Approves Final Dividend for the Financial Year 2022-23

Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.